Meet our team
Predictive Oncology
Corporate Leadership

Raymond F. Vennare
Chief Executive Officer
and Chairman of the Board
Raymond F. Vennare became Predictive Oncology’s CEO and Chairman of the Board on November 1, 2022. He has served on the Board of Directors since September of 2021.
![POAI Headshot[52] POAI Headshot[52]](https://predictive-oncology.com/wp-content/uploads/elementor/thumbs/POAI-Headshot52-e1696341531685-qy1rhrlzxwbn5ivni74jp2zvqx7ghp2c5nub6ca1xg.jpg)
Josh Blacher, MBA
Interim Chief Financial Officer
Josh Blacher, MBA is the Interim Chief Financial Officer for Predictive Oncology. As a strategic and operational CFO with more than 20 years of experience in leadership for private and Nasdaq-listed companies, Mr. Blacher specializes in the life science and biotech sectors.

Arlette H. Uihlein, MD
SVP, Translational Medicine and Drug Discovery, Medical Director
Arlette H. Uihlein, MD, FCAP, FASCP, is Senior Vice President of Translational Medicine and Drug Discovery for Predictive Oncology and Site Leader of Helomics. She has also served as Medical Director of Helomics® Clinical and Research Labs since 2011.
Let’s discover and develop together.
We want to hear about your process challenges—and identify ways to solve them together. Complete the form to get in touch with our team of experts.
News & resources
White paper validates highly reproducible drug response data. Results enable AI platform to model and predict patient outcomes on historical samples Leveraging more than 20...
A recent white paper released by Predictive Oncology’s highlights the challenge of late-stage clinical trial failures and the company’s ability to better navigate those obstacles...
Company expands AI/ML driven capabilities to pursue novel biomarker discovery to predict patient outcomes and drug response in oncology. Read our white paper below that...
